key: cord-0922914-ai4phii5
authors: Ho, Vanda; Tee, Caroline; See, Kay Choong
title: Drug interactions with potential antivirals used for COVID‐19 in older persons
date: 2020-07-21
journal: Geriatr Gerontol Int
DOI: 10.1111/ggi.13970
sha: d2a9dcd59e8d322769c33e992c51aebba431c789
doc_id: 922914
cord_uid: ai4phii5

nan

Older persons are increasing in proportion globally, and retain important social and economic roles. Unfortunately, they experience disproportionately high mortality from severe coronavirus disease 2019 (COVID-19) infection. 1 Cunningham et al. have succinctly highlighted the challenges and potential treatment options. 2 We feel that these options have specific considerations in older adults. To optimize clinical care, we need to be prudent in all areas: clinically, pharmacologically and ethically. In particular, we will highlight the impact of polypharmacy on older adults when potential antivirals for COVID-19 are used.

Although no specific antivirals for COVID-19 infections have been proven to be effective in randomized controlled trials, offlabel, compassionate and experimental use of several drugs are common, especially for severe infection. 3 The risks for severe COVID-19 infection and mortality concurrently increase with age. Similarly, chronic obstructive pulmonary disease, cardiovascular diseases, cerebrovascular diseases, cognitive disorders, chronic kidney disease, chronic liver disease, hyperlipidemia, hypertension, diabetes mellitus and hypothyroidism are all more common in older persons. Multimorbidity interacts significantly with frailty. 4 Not surprisingly, treatment of multiple comorbid conditions necessitates the use of multiple medications.

In the presence of both polypharmacy and multimorbidity, antiviral administration in older adults carries an elevated risk of harm from drug-drug and drug-disease interaction. With regard to drugdrug interactions, we show several commonly-used medications in older persons and their interaction with antiviral medications repurposed for COVID-19 (Table 1) . 5, 6 In addition, aging involves progressive organ impairments that affect drug clearance and pharmacokinetics. For instance, in the presence of moderate-to-severe hepatic impairment, antiviral medications should be avoided. Similarly, in the presence of severe renal dysfunction, i.v. remdesivir is to be used with caution in view of the accumulation of excipient sulfobutylether-β-cyclodextrin. Whereas chloroquine and hydroxychloroquine might require dose attenuation, as they have some clearance through the kidneys.

Letters to the Editor -Research Studies © 2020 Japan Geriatrics Society | 737 The surge of COVID-19 is not currently stopping. Although no age group is spared, older persons are a vulnerable population. Their care should remain optimal through personalizing clinical care and medications. Unfortunately, antiviral medications have not been proven to be clinically effective against COVID-19, and observational data of treatment effects on older persons are limited. Consequently, any potential antivirals for COVID-19 should be prescribed very carefully, considering drug-drug interactions, drug-disease interactions and the balance of benefit versus harm.

Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy

Treatment of COVID-19: old tricks for new challenges

Treating COVID-19-off-label drug use, compassionate use, and randomized clinical trials during pandemics

Principles of Geriatric Medicine and Gerontology

Liverpool Drug Interaction Group. Prescribing Resources

We pay homage to the Japan Geriatrics Society (Prof. Masahiro Akishita, President) and the Subcommittee on Frailty and Sarcopenia (Dr. Hidenori Arai, Chairman) for their prompt announcement to prevent frailty during the pandemic.

None.

The authors declare no conflict of interest.